Key result
Class I antiarrhythmics block cardiac sodium and calcium currents at clinical concentrations in human cardiomyocytes.
Why the study?
The responses of human iPSC-derived cardiomyocytes to class I antiarrhythmic agents remain to be elucidated to predict drug cardiotoxicity.
Class I antiarrhythmic agents block Na+ and Ca2+ currents in human iPSC-derived cardiomyocytes at clinical concentrations, demonstrating the utility of these cells for predicting cardiotoxicity.
Answers are grounded in this paper and cite their sources.
Class I agents may block INa/ICaL at clinical concentrations in iPSC-cardiomyocytes; leaves open their predictive value for human cardiotoxicity.
Human induced pluripotent stem cells (hiPSCs) harboring cardiac myosin heavy chain 6 promoter can differentiate into functional cardiomyocytes called “iCell cardiomyocytes” under blasticidin treatment condition. While iCell cardiomyocytes are expected to be used for predicting cardiotoxicity of drugs, their responses to antiarrhythmic agents remain to be elucidated. We first examined electrophysiological properties of iCell cardiomyocytes and mRNA levels of ion channels and Ca handling proteins, and then evaluated effects of class I antiarrhythmic agents on their Na+ and Ca2+ currents. iCell cardiomyocytes were cultured for 8–14 days (38–44 days after inducing their differentiation), according to the manufacturer's protocol. We determined their action potentials (APs) and sarcolemmal ionic currents using whole-cell patch clamp techniques, and also mRNA levels of ion channels and Ca handling proteins by RT-PCR. Effects of three class I antiarrhythmic agents, pirmenol, pilsicainide and mexiletine, on Na+ channel current (INa) and L-type Ca2+ channel current (ICaL) were evaluated by the whole-cell patch clamp. iCell cardiomyocytes revealed sinoatrial node-type (18%), atrial-type (18%) and ventricular-type (64%) spontaneous APs. The maximum peak amplitudes of INa, ICaL, and rapidly-activating delayed-rectifier K+ channel current were −62.7 ± 13.7, −8.1 ± 0.7, and 3.0 ± 1.0 pA/pF, respectively. The hyperpolarization-activated cation channel and inward-rectifier K+ channel currents were observed, whereas the T-type Ca2+ channel or slowly-activating delayed-rectifier K+ channel current was not detectable. mRNAs of Nav1.5, Cav1.2, Kir2.1, HCN4, KvLQT1, hERG and SERCA2 were detected, while that of HCN1, minK or MiRP was not. The class Ia antiarrhythmic agent pirmenol and class Ic agent pilsicainide blocked INa in a concentration-dependent manner with IC50 of 0.87 ± 0.37 and 0.88 ± 0.16 μM, respectively; the class Ib agent mexiletine revealed weak INa block with a higher IC50 of 30.0 ± 3.0 μM. Pirmenol, pilsicainide and mexiletine blocked ICaL with IC50 of 2.00 ± 0.39, 7.7 ± 2.5 and 5.0 ± 0.1 μM, respectively. In iCell cardiomyocytes, INa was blocked by the class Ia and Ic antiarrhythmic agents and ICaL was blocked by all the class I agents within the ranges of clinical concentrations, suggesting their cardiotoxicity.
No takes yet. Share an insight, caveat, or question.
Yonemizu et al. (2019) studied this question. Class I antiarrhythmic agents (pirmenol, pilsicainide, mexiletine) was evaluated on Na+ channel current (INa) and L-type Ca2+ channel current (ICaL) block (IC50). In human iPS cell-derived cardiomyocytes, class Ia and Ic antiarrhythmic agents blocked INa, and all class I agents blocked ICaL within clinical concentration ranges, suggesting cardiotoxicity.
Synapse has enriched 10 related papers. Consider them for comparative context: